TrialLeukemia2020

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.

Annette M Staiger et al.PubMed ↗Publisher ↗

No numbers read from the abstract.